Global Virus Filtration Market - Segmented by Product (Kits & Reagents, Filtration Systems, Services, and other Products), Application, End-User, and Geography - Growth, Trends and Forecast (2022 - 2030)
Market Overview
The Global Virus Filtration market is projected to grow at a CAGR of approximately 12% during the forecast period (2018-2023). The global Virus Filtration market is experiencing considerable growth due to factors like increasing R&D spending, growth in biopharmaceutical industry, and increasing government support for the pharmaceutical and biotechnology industry.
Growth in Biopharmaceutical Industry
According to estimates, the global biopharmaceuticals market is estimated to reach USD 341.16 billion in 2023. Biotechnology derived medicinal products are presently the best characterized biologicals with considerable production and clinical experience, and have revolutionized the treatment of some of the most difficult-to-treat diseases, prolonging and improving the quality of life and patient care. Opportunities in biopharmaceuticals have been constantly increasing over the past decade. The efficacy and the safety of the drugs are some of the key product features that drive the market’s growth. There have been biopharmaceutical products that are improving the quality of life and reducing the death rates in patients with HIV/AIDs, cancer, cystic fibrosis, and rheumatoid arthritis. Biopharmaceuticals have reduced the number of deaths caused due to cancer and HIV/AIDS in the last decade. The efficacy of the drugs and their safety has increased the acceptance for biopharmaceuticals. This growth in biopharmaceutical industry has spurred the growth of virus filtration market. Virus filtration technologies are both directly and indirectly exploited in biopharmaceutical industry.
Stringent Regulations for Validation of Filtration Products
Some biological therapeutic products are produced using mammalian cell lines or human plasma. The risk of contamination with either known or unknown viruses in these products has been demonstrated; hence, regulatory agencies have mandated that manufacturers evaluate the risks of virus contamination and take necessary measures to mitigate these risks. In addition to ensuring the purity of source materials, manufacturers are encouraged to institute steps in the purification process that will clear endogenous and adventitious viruses. Filtration has been successfully used in numerous processes as a robust step for virus clearance. Regulators require that an overall safety margin, such as <1 virus particle per 10^6 doses, be used to demonstrate the virus safety of the manufacturing process. The drug manufacturer is required to quantify the virus "load" in the process. For biotech products derived from murine cell lines such as Chinese hamster ovaries (CHO) and non-sense oligonucleotide (NSO), this typically translates to ~12–18 log10 clearance for endogenous retroviruses and ~6 log10 removal for adventitious viruses. The US Food and Drug Administration (FDA) requires that manufacturers of biotech products that use murine cell lines are to demonstrate the clearance capability of their manufacturing processes with one relevant retrovirus (murine retrovirus) before starting Phase I studies. Regulatory agencies in Germany and France require that manufacturing processes be evaluated to clear non-enveloped parvoviruses in addition to retroviruses. Before marketing authorization, manufacturers are required to assess clearance of multiple model and relevant viruses in their manufacturing processes. Overall, the stringent nature of the regulations for virus filtration is a major deterrent to the growth of the global virus filtration market.
North America has the Largest Share in Global Virus Filtration Market
The global Virus Filtration market has been segmented into five major regions, viz. North America, Europe, Asia Pacific, Middle East & Africa, and South America. Driven by the developed country of the U.S., North America dominated the global Virus Filtration market in 2017, due to factors such as increasing R&D activities in biopharmaceutical industry, growth of chronic illnesses, and also due increasing government interest in reducing burden of infections.
Key Developments in Virus Filtration Market
• Dec 2017: Asahi Kasei Medical announced the construction of a new plant for the production of cellulose hollow-fiber membranes for PlanovaTMvirus removal filters in Nobeoka, Miyazaki, Japan, increasing annual production capacity by 40,000 m2/year. The construction is schedule to complete in May 2019.
Major Players: ASAHI KASEI MEDICAL CO. LTD., CHARLES RIVER LABORATORIES INTERNATIONAL INC., GENERAL ELECTRIC COMPANY, LONZA GROUP LTD., MERCK KGAA, PALL CORPORATION, SARTORIUS AG, SIGMA-ALDRICH CORPORATION, THERMO FISCHER SCIENTIFIC INC., AND WUXI PHARMATECH (CAYMAN) INC. among others.
Reasons to Purchase this Report
• Current and future Global Virus Filtration Market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3-month analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
The Global Virus Filtration market is projected to grow at a CAGR of approximately 12% during the forecast period (2018-2023). The global Virus Filtration market is experiencing considerable growth due to factors like increasing R&D spending, growth in biopharmaceutical industry, and increasing government support for the pharmaceutical and biotechnology industry.
Growth in Biopharmaceutical Industry
According to estimates, the global biopharmaceuticals market is estimated to reach USD 341.16 billion in 2023. Biotechnology derived medicinal products are presently the best characterized biologicals with considerable production and clinical experience, and have revolutionized the treatment of some of the most difficult-to-treat diseases, prolonging and improving the quality of life and patient care. Opportunities in biopharmaceuticals have been constantly increasing over the past decade. The efficacy and the safety of the drugs are some of the key product features that drive the market’s growth. There have been biopharmaceutical products that are improving the quality of life and reducing the death rates in patients with HIV/AIDs, cancer, cystic fibrosis, and rheumatoid arthritis. Biopharmaceuticals have reduced the number of deaths caused due to cancer and HIV/AIDS in the last decade. The efficacy of the drugs and their safety has increased the acceptance for biopharmaceuticals. This growth in biopharmaceutical industry has spurred the growth of virus filtration market. Virus filtration technologies are both directly and indirectly exploited in biopharmaceutical industry.
Stringent Regulations for Validation of Filtration Products
Some biological therapeutic products are produced using mammalian cell lines or human plasma. The risk of contamination with either known or unknown viruses in these products has been demonstrated; hence, regulatory agencies have mandated that manufacturers evaluate the risks of virus contamination and take necessary measures to mitigate these risks. In addition to ensuring the purity of source materials, manufacturers are encouraged to institute steps in the purification process that will clear endogenous and adventitious viruses. Filtration has been successfully used in numerous processes as a robust step for virus clearance. Regulators require that an overall safety margin, such as <1 virus particle per 10^6 doses, be used to demonstrate the virus safety of the manufacturing process. The drug manufacturer is required to quantify the virus "load" in the process. For biotech products derived from murine cell lines such as Chinese hamster ovaries (CHO) and non-sense oligonucleotide (NSO), this typically translates to ~12–18 log10 clearance for endogenous retroviruses and ~6 log10 removal for adventitious viruses. The US Food and Drug Administration (FDA) requires that manufacturers of biotech products that use murine cell lines are to demonstrate the clearance capability of their manufacturing processes with one relevant retrovirus (murine retrovirus) before starting Phase I studies. Regulatory agencies in Germany and France require that manufacturing processes be evaluated to clear non-enveloped parvoviruses in addition to retroviruses. Before marketing authorization, manufacturers are required to assess clearance of multiple model and relevant viruses in their manufacturing processes. Overall, the stringent nature of the regulations for virus filtration is a major deterrent to the growth of the global virus filtration market.
North America has the Largest Share in Global Virus Filtration Market
The global Virus Filtration market has been segmented into five major regions, viz. North America, Europe, Asia Pacific, Middle East & Africa, and South America. Driven by the developed country of the U.S., North America dominated the global Virus Filtration market in 2017, due to factors such as increasing R&D activities in biopharmaceutical industry, growth of chronic illnesses, and also due increasing government interest in reducing burden of infections.
Key Developments in Virus Filtration Market
• Dec 2017: Asahi Kasei Medical announced the construction of a new plant for the production of cellulose hollow-fiber membranes for PlanovaTMvirus removal filters in Nobeoka, Miyazaki, Japan, increasing annual production capacity by 40,000 m2/year. The construction is schedule to complete in May 2019.
Major Players: ASAHI KASEI MEDICAL CO. LTD., CHARLES RIVER LABORATORIES INTERNATIONAL INC., GENERAL ELECTRIC COMPANY, LONZA GROUP LTD., MERCK KGAA, PALL CORPORATION, SARTORIUS AG, SIGMA-ALDRICH CORPORATION, THERMO FISCHER SCIENTIFIC INC., AND WUXI PHARMATECH (CAYMAN) INC. among others.
Reasons to Purchase this Report
• Current and future Global Virus Filtration Market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares and strategies employed by the major market players.
• 3-month analyst support along with the Market Estimate sheet (in Excel).
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
